WILSON TROY EDWARD 4

What Happened
Troy Edward Wilson, a director of Avidity Biosciences (RNAM), disposed of a total of 117,325 securities on Feb 27, 2026 pursuant to the Merger Agreement with Novartis. The breakdown: 78,802 shares of common stock (including previously reported RSUs) and 38,523 derivative securities (options). Common-stock consideration under the deal is $72.00 per share (≈ $5.67M for the 78,802 shares); the options were cashed out under the merger for an amount equal to the difference between the $72 merger price and each option’s exercise price.

Key Details

• Transaction date: 2026-02-27. Transaction code: D (Disposition to issuer, per merger terms).
• Reported disposals: 65,091 shares; 13,711 shares; 10,034 derivative; 13,489 derivative; 15,000 derivative — total 117,325 securities.
• Price reported: N/A on the Form 4 for direct dispositions (to issuer). Merger consideration = $72.00/share for common stock; options paid in cash equal to ($72 − exercise price).
• Common-stock portion value: 78,802 shares × $72 ≈ $5,673,744. Option payouts depend on exercise prices and are not specified.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing/period date: 2026-02-27 (filed same day); appears timely and tied to the announced merger (Merger Agreement dated Oct 25, 2025).

Context
These dispositions were part of the negotiated merger with Novartis and reflect deal consideration and option cashouts, not an open-market sale. For derivative items: options were not converted into long-held shares but were cashed out for the spread under the merger terms. Such deal-driven disposals are routine and driven by contract terms rather than an insider’s market view.